

promoting access to White Rose research papers



Universities of Leeds, Sheffield and York
<http://eprints.whiterose.ac.uk/>

This is an author produced version of a paper published in **Organic Letters**.
White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/77264/>

Paper:

James, T, Simpson, I, Grant, JA, Sridharan, V and Nelson, A (2013) *Modular, Gold-Catalyzed Approach to the Synthesis of Lead-like Piperazine Scaffolds*. *Organic Letters*, 15 (23). 6094 - 6097.

<http://dx.doi.org/10.1021/ol402988s>

A modular, gold-catalysed approach to the synthesis of lead-like piperazine scaffolds

Thomas James, Iain Simpson, J. Andrew Grant, Visuvanathar Sridharan and Adam Nelson*


School of Chemistry, University of Leeds, LS2 9JT, UK, Astbury Centre for Structural Molecular Biology, University of Leeds, LS2 9JT, UK, and AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

a.s.nelson@leeds.ac.uk

In memory of J. Andrew Grant: a great colleague, collaborator and scientist

Received Date (will be automatically inserted after manuscript is accepted)

ABSTRACT



Ring-opening of cyclic sulfamidates with propargylic sulfonamides yielded substrates for a gold-catalysed cyclisation to yield tetrahydropyrazines. Manipulation of the tetrahydropyrazines, by reduction or using multicomponent reactions, yielded piperazine scaffolds in which substitution of the carbon atoms was varied. Such scaffolds may have value in the synthesis of novel screening compounds with lead-like molecular properties.

Sourcing large numbers of diverse, lead-like small molecules is a major challenge in maintaining high quality screening collections.^{1,2} This challenge stems both from the poor availability of lead-like compounds,² and the historically uneven exploration of chemical space by synthesis.³ As an example, many commercially-available screening compounds and bioactive molecules contain a piperazine ring (5.4% of the ZINC database and 7.7% of the ChEMBL database respectively; Supporting Information). Yet, in the vast majority of these compounds, the piperazine ring is isolated and is not substituted on any of its carbon atoms. Such piperazines are widely exploited in drug discovery because they allow the medicinal chemist to design molecules that may be grown in two directions whilst retaining basicity through

appropriate substitution. As a result, many important bioactive small molecules are piperazines, including 13 of the 200 best-selling drugs in 2012.⁴

In this paper, we describe an approach to the synthesis of substituted piperazines from pairs of bi-connective⁵ building blocks (Scheme 1).⁶ Ring-opening of a cyclic sulfamidate **1**,^{7,8} prepared from the corresponding amino alcohol, with a propargylic sulfonamide **2** would yield a substrate, **3**, for a cyclisation reaction. Metal-catalysed

⁴ The structures of the top 200 selling drugs can be downloaded from: <http://cbc.arizona.edu/njardarson/group>: McGrath N. A.; Brichacek M.; Njardarson, J. T. *J. Chem. Educ.* **2010**, *87*, 1348.

⁵ MacLellan, P.; Nelson, A. *Chem. Commun.* **2013**, 2383.

⁶ For a recent approach to substituted piperazines, see: Ruider, S. A.; Müller, S.; Carreira, E. M. *Angew. Chem. Int. Ed.* **2013**, doi: 10.1002/anie.201306563.

⁷ For a review of the application of cyclic sulfamidates in heterocycle synthesis, see: Bower, J. F.; Rujirawanich, J.; Gallagher, T. *Org. Biomol. Chem.* **2010**, *8*, 1505.

⁸ Williams, A. J.; Chakthong, S.; Gray, D.; Lawrence, R. M.; Gallagher, T. *Org. Lett.* **2003**, *5*, 811.


¹ Krier, M.; Bret, G.; Rognan, D. *J. Chem. Inf. Model.*, **2006**, *46*, 512.

² Nadin, A.; Hattotuwigama, C.; Churcher, I. *Angew. Chem. Int. Ed.* **2012**, *51*, 1114.

³ Lipkus, A. H.; Yuan, Q.; Lucas, K. A.; Funk, S. A.; Bartelt, W. F.; Schenck, R. J.; Trippe, A. J. *J. Org. Chem.* **2008**, *73*, 4443.


cyclisation^{9,10} of the *N*-Boc- (or *N*-Cbz-) protected amine onto the alkyne would then yield a heterocyclic product **4**. This synthesis of tetrahydropyrazines **4** from the bi-connective building blocks **1** and **2** may be classified as a *bi/bi* process⁵ or as an ambiphile¹¹ pairing reaction sequence. It was envisaged that the ene-diamine functionality might serve as a useful handle for decoration to yield small molecules with lead-like² properties.

Scheme 1. Overview of the proposed modular synthetic approach.^a



^aR = Boc or Cbz; R' = *o*- or *p*-nitrophenylsulfonyl.

Table 1. Optimisation of the synthesis of the tetrahydropyrazine **6a**^a



entry	conditions	yield 6a / %
1	5 mol% Au(PPh ₃)Cl, 5 mol% AgSbF ₆ , dioxane, 100 °C, μw, 10 min	98
2	5 mol% Au(PPh ₃)Cl, 5 mol% AgSbF ₆ , dioxane, 100 °C, 3 h	95
3	5 mol% Au(PPh ₃)Cl, 5 mol% AgSbF ₆ , CH ₂ Cl ₂ , rt, 16 h ^c	83 ^d
4	1 mol% Au(IPr)Cl, ^b 1 mol% AgSbF ₆ , dioxane, 100 °C, μw, 10 min	97

^aNs = *o*-nitrophenylsulfonyl. ^bIPr = 1,3-Bis(2,6-diisopropylphenyl)-1,3-dihydro-2*H*-imidazol-2-ylidene. ^cAnalysis of the crude reaction mixture by 500 MHz ¹H NMR spectroscopy revealed a 85:15 mixture of the tetrahydropyrazine **6a** and the ketone **7a**. ^dThe ketone **7a** was also obtained in 15% yield.

Initially, the cyclisation of the substrate **5a** (and subsequent double bond isomerisation¹⁰) was investigated

(Table 1).¹² With 5 mol% Au(PPh₃)Cl and 5 mol% AgSbF₆¹³ in dioxane at 100 °C with microwave irradiation, the tetrahydropyrazine **6a** was obtained in 98% yield after 10 min (Table 1, entry 1). With heating at 100 °C in dioxane, **6a** was obtained in 95% yield, although a longer reaction time (3 h) was required (Table 1, entry 2). At room temperature in dichloromethane, **6a** (83%) was accompanied by the ketone **7a** (15%) (Table 1, entry 3). Additional experiments demonstrated that the ketone **7a** is a kinetic product of this reaction, and is a competent intermediate in the formation of the thermodynamic product, **6a**. Cyclisation was also effective with 1 mol% of the *N*-heterocyclic carbene complex¹⁴ Au(IPr)Cl and 1 mol% AgSbF₆, yielding **6a** in 97% yield (Table 1, entry 4).




Figure 1. Structures of building blocks. Ns = *o*-nitrophenylsulfonyl; Ns' = *p*-nitrophenylsulfonyl.

A range of building blocks (Figure 1) was prepared to allow the investigation of the scope and limitations of the cyclisation reaction. The potential substrates **5** were prepared by treatment of a propargylic sulfonamide **8** with sodium hydride in DMF, and reaction with a cyclic sulfamidate **9** (Table 2).

⁹ For other similar cyclisations, see: (a) Nicolai, S.; Waser, J. *Org. Lett.* **2011**, *13*, 6324. (b) Han, J.; Xu, B.; Hammond, G. B. *J. Am. Chem. Soc.* **2010**, *132*, 916.

¹⁰ For cyclisations of *N*-propargyl amides to yield oxazoles, see: (a) Hashmi, A. S. K.; Weyrauch, J. P.; Frey, W.; Bats, J. W. *Org. Lett.* **2004**, *6*, 4391; (b) Weyrauch, J. P.; Hashmi, A. S. K.; Schuster, A.; Hengst, T.; Schetter, S.; Littmann, A.; Rudolph, M.; Hamzic, M.; Visus, J.; Rominger, F.; Frey, W.; Bats, J. W. *Chem. Eur. J.* **2010**, *16*, 956.

¹¹ Rolfe, A.; Samarakoon, T. B.; Hanson, P. R. *Org. Lett.* **2010**, *12*, 1216.

¹² (a) Li, Z.; Brouwer, C.; He, C. *Chem. Rev.* **2008**, *108*, 3239. (b) Ito, H.; Harada, T.; Ohmiya, H.; Sawamura, M. *Beilstein J. Org. Chem.* **2011**, *7*, 951. (c) Zhang, Y.; Donahue, J. P.; Li, C.-J. *Org. Lett.* **2007**, *9*, 627. (d) Kang, J.-E.; Kim, H.-B.; Lee, J.-W.; Shin, S. *Org. Lett.* **2006**, *8*, 3537. (e) Müller, T. E.; Grosche, M.; Herdtweck, E.; Pleier, A.-K.; Walter, E.; Yan, Y.-K. *Organometallics* **2000**, *19*, 170.

¹³ Teles, J. H.; Brode, S.; Chabanas, M. *Angew. Chem. Int. Ed.* **1998**, *37*, 1415.

¹⁴ Marion, N.; Ramón, R. S.; Nolan, S. P. *J. Am. Chem. Soc.* **2009**, *131*, 448.

Table 2. Synthesis and gold-catalysed reactions of alkyne substrates (see Figure 2)

entry	building blocks	substrate ^a (Method ^b , yield)	Product ^a (Method ^b , yield)
1	8a, 9b	5b (A1, 95%)	6b (B1, 98%)
2	8a, 9c	5c (A1, 72%)	6c (B1, 90%)
3	8b, 9d	5d (A1, 70%)	6d (B1, 96%)
4	8a, 9e	5e (A1, 94%)	6e (B1, 96%)
5	8b, 9f	5f (A1, 68%)	6f (B1, 36%) ^c
6		5f	10 (B2, 81%)
7	8b, 9f	5g (A2, 74%)	6g (B1, 79%)
8	8b, 9g	5h (A2, 67%)	6h (B1, 85%)
9	8b, 9h	5i (A1, 89%)	6i (B1, 92%)
10	8c, 9a	5j (A1, >98%)	7b (B3, 68%)
11	8d, 9b	5k (A1, 91%)	7c (B3, 85%)
12	8e, 9b	5l (A1, 90%)	7d (B3, 46%)
13	8c, 9i	5m (A1, 83%)	7e (B3, 61%)

^aNs = *o*-nitrophenylsulfonyl; Ns' = *p*-nitrophenylsulfonyl. ^bMethods: A1: **8**, NaH (1.1 eq), DMF then **9** then 5 M HCl; A2: **8**, NaH (1.1 eq), DMF then **9** then 1M citric acid solution; B1: 5 mol% Au(PPh₃)Cl, 5 mol% AgSbF₆, dioxane, 100 °C; B2: 5 mol% Au(PPh₃)Cl, 5 mol% AgSbF₆, CDCl₃, rt; B3: 1 mol% Au(IPr)Cl, 1 mol% AgSbF₆, 2:1 dioxane–H₂O, 120 °C, sealed tube (IPr = 1,3-Bis(2,6-diisopropylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene). ^c**10** was also obtained in 48% yield.




Figure 2. Structures of the substrates **5f-g** and the products of gold-catalysed reactions. ^aNs = *o*-nitrophenylsulfonyl; Ns' = *p*-nitrophenylsulfonyl.

The cyclisation substrates **5b-i** were treated with 5 mol% Au(PPh₃)Cl and 5 mol% AgSbF₆ in dioxane at 100

°C (Table 2 and Figure 2). Under these conditions, the substrates **5b-e** and **5g-i** cyclised smoothly to give the corresponding tetrahydropyrazines in 79-98% yield. This study demonstrated that either a Boc- or a Cbz-protected amine is a competent nucleophile in the cyclisation. However, **5f** possesses two potential nucleophiles – a Boc-protected amine and an alcohol – positioned at the same distance from the alkyne: at 100 °C in dioxane, the two possible products, **6f** and **10**,¹⁵ were obtained in 36% and 48% yield respectively. The outcome was controlled at room temperature, and the dihydrooxazine **10** (81%) was the only product observed.

The reactions of **5j-m** could be controlled by using 1 mol% Au(IPr)Cl and 1 mol% AgSbF₆ in 2:1 dioxane–H₂O at 120 °C in a sealed tube (entries 10-13, Table 2); under these conditions, highly regioselective hydration of the alkyne was observed.^{16,17} With the 1,2-disubstituted alkynes **5j**, **5k** and **5m**, hydration occurred distal to the NNs group, which might be explained by the intermediacy of a chelated intermediate (Figure 3).^{18,19}




Figure 3. Proposed intermediate in the highly regioselective hydration of the 1,2-disubstituted alkynes **5j**, **5k** and **5m**.

The tetrahydropyrazines **6c-d** and **6i**, and the ketone **7d**, were reduced to the corresponding piperazines by treatment with triethylsilane and trifluoroacetic acid (Figure 4). The sense of diastereoselectivity depended on the identity of the carbamate protecting group. With the Cbz-protected substrate **6c**, the 2,6-*trans*-disubstituted piperazine **11a** was obtained predominantly, presumably as a result of axial attack of the reducing agent on the conformation of the intermediate iminium ion in which 1,3-strain²⁰ is minimized. The Boc-protected substrates **6d** and **6i** yielded predominantly the 2,6-*cis*-disubstituted piperazines **11b** and **11c**; here, Boc deprotection may precede reduction via an alternative reactive conformation. Finally, reductive amination of the NHCbz-substituted ketone **7d** yielded highly selectively the 2,3-*cis*-disubstituted piperazine **11d**.

¹⁵ For a base-catalysed cyclisation to give 1,4-oxazines, see: Vandavasi, J. K.; Hu, W.-P.; Chen, H.-Y.; Senadi, G. C.; Chen, C.-Y.; Wang, J.-J. *Org. Lett.* **2012**, *14*, 3134.

¹⁶ In contrast, the reactions of **5j-m**, catalysed by 5 mol% Au(PPh₃)Cl and 5 mol% AgSbF₆ in dioxane at 100 °C, were not clean.


¹⁷ See also: Hashmi, A. S. K.; Molinari, L.; Rominger, F.; Oeser, T. *Eur. J. Org. Chem.* **2011**, 2256.

¹⁸ Tsukano, C.; Yokouchi, S.; Girard, A.-L.; Kuribayashi, T.; Sakamoto, S.; Enomoto, T.; Takemoto, Y. *Org. Biomol. Chem.* **2012**, *10*, 6074.

¹⁹ For a related directing effect, see: Hansmann, M. M.; Rudolph, M.; Rominger, F.; Hashmi, S. K. A. *Angew Chem. Int. Ed.* **2013**, *52*, 2593.


²⁰ Hoffmann, R. W. *Chem. Rev.* **1989**, *89*, 1841.

Figure 4. Products of the reductions of the tetrahydropyrazines **6** and the ketone **7d**^{a,b}



^aWhere appropriate, the major diastereomeric product is drawn.
^bMethod: TFA (10 eq.), Et₃SiH (6 eq.), CH₂Cl₂, 0 °C → rt.

Figure 5. Products of the multicomponent reactions of the tetrahydropyrazines **6** and the ketone **7b**^{a,b}




^aWhere appropriate, the major diastereomeric product is drawn.
^bMethod: 1. TFA, CH₂Cl₂ then evaporate; 2. Benzylisocyanide or 2-morpholinoethylisocyanide, EtOH, 0 °C.

Multicomponent reactions of the tetrahydropyrazines **6a** and **6i** and the NHBoc-substituted ketone **7b** were also investigated (Figure 5). In each case, the substrate was treated with TFA in dichloromethane, evaporated and treated with an isocyanide in ethanol. The tetrahydropyrazines **6a** and **6i** yielded the differentially-protected piperazine carboxylic acid derivatives **12a-b**.²¹ The reaction of **6i** was highly (>98:<2) diastereoselective; the sense of diastereoselectivity may stem from minimisation of steric interactions in the product-

determining transition state of the Mumm rearrangement (Figure 6).²² Finally, the ketone **7b** was converted into the 1,4-diazepane **13** in 71% yield.

Figure 6. Rationalisation of stereochemical outcome of the multicomponent reaction of **6i**



In summary, we have developed a modular approach to the synthesis of lead-like piperazine scaffolds. The approach involves reaction between cyclic sulfamidate and propargylic sulfonamide building blocks to yield substrates for a gold-catalysed cyclisation reaction. Crucially, by variation of the specific building blocks used, it was possible to vary the substitution and relative configuration of the piperazine scaffolds obtained. It is envisaged that the approach may be exploited in the synthesis of libraries of substitutionally-diverse piperazines with lead-like molecular properties.

Acknowledgment We thank AstraZeneca and EPSRC for funding.

Supporting Information Available (“Supporting Information” on the Styles toolbar).

²¹ Bowers, M. M.; Carroll, P.; Joullié, M. M. *J. Chem. Soc. Perkin Trans. 1* **1989**, 857.

²² El Kaim, L.; Grimaud, L. *Tetrahedron* **2009**, 65, 2153.